December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

47.19 +3.25 (+7.40%)
Streaming Delayed Price Updated: 2:32 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
What 6 Analyst Ratings Have To Say About Structure Therapeutics ↗
 
Via Benzinga
News headline image
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Should You Still Buy the Nasdaq's Best-Performing October Stocks? ↗
Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them. 
Via The Motley Fool
News headline image
Top 5 Health Care Stocks That Should Keep You Up At Night ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023 ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Structure Therapeutics ↗
 
Via Benzinga
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
BMO Capital Maintains Outperform Rating for Structure Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Why Shares of Structure Therapeutics Are Up Monday ↗
The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug. 
Via The Motley Fool
News headline image
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Shares of Structure Therapeutics Are Soaring on Friday ↗
The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate. 
Via The Motley Fool
News headline image
Nasdaq Gains Over 1%; Nike Posts Upbeat Earnings ↗
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded up 0.24% to 33,746.70 while the NASDAQ rose 1.22% to 13,362.51. The S&P 500 also rose,... 
Via Benzinga
Topics Stocks
News headline image
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66% ↗
The company is working on a pill to help weight loss, rivaling shots from Novo and, possibly, Lilly. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today? ↗
Structure Therapeutics Inc (NASDAQ: GPCR) released results from the Phase 1b multiple ascending dose (MAD) study of GSBR-1290 in healthy, overweight, or  
Via Benzinga
News headline image
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser... 
Via Benzinga
News headline image
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Tuesday. Here are some big stocks recording gains in today’s session. Paymentus Holdings, Inc. (NYSE: PAY) shares rose 29.4% to... 
Via Benzinga
News headline image
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗
 
Via Benzinga
News headline image
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly? ↗
An overweight world is hungry for new treatments. For now, two companies own the market. 
Via Investor's Business Daily
News headline image
Why Shares of Structure Therapeutics Rose Monday ↗
The company's lead diabetes and weight-loss therapy may benefit from a decision by Pfizer. 
Via The Motley Fool
News headline image
Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Cava Stock Makes A Stand In Mixed IPO Landscape: Where Does It Rank Against Other 2023 Wall Street Debuts? ↗
In a year that’s seen a sharp decline in initial public offerings, Washington, D.C.-based Mediterranean restaurant chain Cava Group (NYSE: CAVA) made a striking first public appearance on the New York... 
Via Benzinga
News headline image
This Biotech Is Developing The Next Ozempic. Should You Buy It? ↗
If it succeeds, it'll still face a battle for market share. 
Via The Motley Fool
News headline image
Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years ↗
If you can tolerate the risk and have some patience, both stocks could blossom. 
Via The Motley Fool
News headline image
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
From Structure Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.